Zydus Lifesciences receives USFDA final approval for Nitroglycerin Sublingual Tablets

16 Mar 2022 , 01:33 AM

Zydus Lifesciences has received final approval from the USFDA to market Nitroglycerin Sublingual Tablets in the strengths of 03 mg 04mg and 06mg US RLD Nitrostat Sublingual Tablets Nitroglycerin Sublingual Tablets are used to relieve chest pain angina in people who have a certain heart condition coronary artery disease It may also be used before physical activities to help prevent chest pain Nitroglycerin belongs to a class of drugs known as nitrates Angina occurs when the heart muscle is not getting enough blood This drug works by relaxing and widening blood vessels so blood can flow more easily to the heart The drug will be manufactured at the groups formulation manufacturing facility at SEZ Ahmedabad